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ESMO Minimum Clinical Recommendations for the diagnosis,
treatment and follow-up of acute myeloblastic leukemia (AML)
in adult patients
Incidence
. The crude incidence of AML in adults in Europe is
5–8/100 000 per year. The mortality is approximately
4–6/100 000 per year.
Diagnosis
. The diagnosis of AML requires examination of peripheral
blood samples and bone marrow aspirates. Work-up should
comprise morphological examination, cytochemistry, immu-
nophenotyping and cytogenetic analysis.
Risk assessment
. Risk assessment in AML includes the patient’s age, the
initial leukocyte count, the AML subtype, karyotype data,
and medical conditions in the patient’s history which may
affect the feasibility of intensive chemotherapy. Elderly
patients (>60 yrs.) have an adverse prognosis if MDR-posi-
tivity or unfavorable genetic changes are present and are
more susceptible to treatment complications. AML with the
chromosomal translocations t(15;17) (i.e. acute promyelo-
cytic leukemia; APL), t(8;21) and inv(16) including acute
myelo-monocytic leukemia with preponderance of eosino-
phil granulocytes are considered as favorable [II, A]. An
antecedent or concomitant myelodysplastic syndrome or
complex aberrant karyotypes are adverse prognostic factors.
. If fungal infection is suspected a thoracic CT-scan and an
abdominal ultrasound or a CT-scan may be performed to
assess liver, spleen, lymph nodes and kidneys for possible
pathological alterations. Cardiac examination including
echocardiography is recommended for patients with risk
factors or a history of heart disease [A].
. In addition to hematological and chemistry tests a coagu-
lation screening is to be performed prior to the insertion of
central venous lines. HLA typing should be performed on
patients who are candidates for an allogeneic bone marrow
or stem cell transplant, and should include their family
members [A].
Treatment plan
. Treatment is divided into induction and consolidation che-
motherapy. Whenever possible, treatment should be planned
with a curative intent. Candidates for allogeneic stem cell
transplantation should be identified early during induction.
Patients with poor performance status and considerable co-
morbidity, as well as elderly patients not eligible for cura-
tive treatment should receive supportive care.
. Whenever possible, AML treatment should be in clinical
trials and in centres offering a multidisciplinary approach.
Such centres should provide an adequate infrastructure
including a full hematology and medical oncology service, a
close collaboration with a bone marrow transplant unit, as
well as adequate infectious disease and transfusion services.
Induction chemotherapy
. Chemotherapy should be postponed until satisfactory
material for all diagnostic tests has been harvested. Patients
with excessive leukocytosis at presentation may require
emergency leukapheresis prior to induction chemotherapy.
. Induction chemotherapy should include an anthracycline
and cytosine arabinoside [II, A]. Patients failing to respond
to 1–2 cycles of such treatment are considered refractory.
. APL induction chemotherapy should consist of an anthra-
cycline and all-trans retinoic acid (ATRA) [II, A].
Consolidation therapy
. Patients entering clinical and hematological remission
should receive one to two cycles of post-remission therapy
[II, A]. There is no consensus on a single preferred post
remission treatment strategy. Patients with good risk fea-
tures as defined above should receive chemotherapy only,
preferably including high-dose cytarabine. Other patients
with an HLA-identical sibling are candidates for allogeneic
stem cell transplantation in first remission [III, A]. Patients
with particular poor risk features and no donor in their
family may qualify for allogeneic transplant with an unre-
lated matched donor [III, A]. The role of high-dose consoli-
dation chemotherapy with autologous peripheral stem cell
support in AML is controversial. In APL, postremission
consolidation with 1 to 2 cycles of chemotherapy should
include ATRA. Maintenance chemotherapy and ATRA are
beneficial in APL [III, A].
Therapy of relapsed or refractory patients
. Patients in second or subsequent remission may qualify for
allogeneic transplantation with an unrelated donor.
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. In relapsed APL arsenic trioxide can induce remission even
if patients have become refractory to ATRA [III, B].
Response evaluation
. Response to induction is monitored through clinical examin-
ation, serial peripheral blood counts and bone marrow aspi-
rates. During induction-induced aplasia a bone marrow
aspirate should be obtained to monitor for early marrow
response or leukemic blast persistence. The usual require-
ments of AML remission are a normal cellularity of the
bone marrow, morphologically normal hematopoiesis and
blast levels <5% at evaluation of bone marrow smears [B].
. For certain risk categories of APL patients molecular fol-
low-up is recommended [III, C].
Follow-up
. Patients are followed clinically with hematological examin-
ation to detect early relapse. Serial bone marrow examin-
ation is of uncertain value in remission patients without any
clinical or hematological evidence of relapse.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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